[{"id":"76d3be7f-1ce4-4404-98c7-4c495cf2ba18","acronym":"","url":"https://clinicaltrials.gov/study/NCT03816319","created_at":"2021-01-29T07:18:38.008Z","updated_at":"2024-07-02T16:35:08.645Z","phase":"Phase 1","brief_title":"TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03816319","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAK-243"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 08/30/2024","start_date":" 08/30/2024","primary_txt":" Primary completion: 12/11/2024","primary_completion_date":" 12/11/2024","study_txt":" Completion: 12/11/2024","study_completion_date":" 12/11/2024","last_update_posted":"2024-04-19"}]